Literature DB >> 27011902

High-risk corneal allografts: A therapeutic challenge.

Tian Yu1, Vijayalakshmi Rajendran1, May Griffith1, John V Forrester1, Lucia Kuffová1.   

Abstract

Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86% at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in "low-risk" settings. Furthermore, although corneal graft survival in "low-risk" recipients is favourable, the prognosis in "high-risk" recipients for corneal graft is poor. In "high-risk" grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of "high-risk" recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in "high-risk" recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both "low-risk" and "high-risk" hosts.

Entities:  

Keywords:  Cell-based immunomodulation; Collagen-based hydrogels; Graft rejection; Keratoprosthesis; Systemic immunosuppression; “High-risk” grafts

Year:  2016        PMID: 27011902      PMCID: PMC4801785          DOI: 10.5500/wjt.v6.i1.10

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  213 in total

Review 1.  Graft failure IV. Immunologic mechanisms of corneal transplant rejection.

Authors:  Eva-Marie Chong; M Reza Dana
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

2.  CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis.

Authors:  Sushma Hegde; Clay Beauregard; Elizabeth Mayhew; Jerry Y Niederkorn
Journal:  Transplantation       Date:  2005-01-15       Impact factor: 4.939

3.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

4.  Reconstruction of functional ocular surface by acellular porcine cornea matrix scaffold and limbal stem cells derived from human embryonic stem cells.

Authors:  Jing Zhu; Kai Zhang; Yuan Sun; Xuan Gao; Yingchao Li; Zijiang Chen; Xinyi Wu
Journal:  Tissue Eng Part A       Date:  2013-08-14       Impact factor: 3.845

5.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

6.  IL-17A-dependent CD4+CD25+ regulatory T cells promote immune privilege of corneal allografts.

Authors:  Khrishen Cunnusamy; Peter W Chen; Jerry Y Niederkorn
Journal:  J Immunol       Date:  2011-05-06       Impact factor: 5.422

7.  Human mesenchymal stem cells isolated from the umbilical cord.

Authors:  Chun Qiao; Wenrong Xu; Wei Zhu; Jiabo Hu; Hui Qian; Qing Yin; Runqiu Jiang; Yongmin Yan; Fei Mao; Huan Yang; Xingzhong Wang; Yongchang Chen
Journal:  Cell Biol Int       Date:  2007-08-19       Impact factor: 3.612

8.  Transplantation of human embryonic stem cells onto a partially wounded human cornea in vitro.

Authors:  Charles Hanson; Thorir Hardarson; Catharina Ellerström; Markus Nordberg; Gunilla Caisander; Mahendra Rao; Johan Hyllner; Ulf Stenevi
Journal:  Acta Ophthalmol       Date:  2012-01-26       Impact factor: 3.761

9.  Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium.

Authors:  G Pellegrini; C E Traverso; A T Franzi; M Zingirian; R Cancedda; M De Luca
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

10.  Functional antigen matching in corneal transplantation: matching for the HLA-A, -B and -DRB1 antigens (FANCY) - study protocol.

Authors:  Daniel Böhringer; Gabriele Ihorst; Birgit Grotejohann; Julia Maurer; Eric Spierings; Thomas Reinhard
Journal:  BMC Ophthalmol       Date:  2014-12-13       Impact factor: 2.209

View more
  12 in total

Review 1.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

2.  Boston keratoprosthesis type 1: outcomes of the first 38 cases performed at Moorfields Eye Hospital.

Authors:  Chameen Samarawickrama; Nicholas Strouthidis; Mark R Wilkins
Journal:  Eye (Lond)       Date:  2018-02-14       Impact factor: 3.775

3.  Tocilizumab promotes corneal allograft survival in rats by modulating Treg-Th17 balance.

Authors:  Xiao-Song Wu; Xiao-Li Lu; Jing Wu; Ming Ma; Jian Yu; Zhen-Yu Zhang
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

4.  Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo.

Authors:  Suneel Gupta; Michael K Fink; Duraisamy Kempuraj; Nishant R Sinha; Lynn M Martin; Landon M Keele; Prashant R Sinha; Elizabeth A Giuliano; Nathan P Hesemann; Sudhanshu P Raikwar; Shyam S Chaurasia; Rajiv R Mohan
Journal:  Mol Ther       Date:  2022-07-02       Impact factor: 12.910

Review 5.  The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?

Authors:  Arezoo Gowhari Shabgah; Farhad Jadidi-Niaragh; Hamed Mohammadi; Farnoosh Ebrahimzadeh; Maziar Oveisee; Abbas Jahanara; Jamshid Gholizadeh Navashenaq
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

6.  Biomaterials-enabled cornea regeneration in patients at high risk for rejection of donor tissue transplantation.

Authors:  M Mirazul Islam; Oleksiy Buznyk; Jagadesh C Reddy; Nataliya Pasyechnikova; Keith M Meek; Virender S Sangwan; May Griffith; Emilio I Alarcon; Sally Hayes; Philip Lewis; Per Fagerholm; Chaoliang He; Stanislav Iakymenko; Wenguang Liu
Journal:  NPJ Regen Med       Date:  2018-01-31

7.  The effects of local administration of mesenchymal stem cells on rat corneal allograft rejection.

Authors:  Zhe Jia; Fei Li; Xiaoyu Zeng; Ying Lv; Shaozhen Zhao
Journal:  BMC Ophthalmol       Date:  2018-06-08       Impact factor: 2.209

8.  The Balance of Th1/Th2 and LAP+Tregs/Th17 Cells Is Crucial for Graft Survival in Allogeneic Corneal Transplantation.

Authors:  Shang Li; Jing Yu; Chungang Guo; Ying Jie; Zhiqiang Pan
Journal:  J Ophthalmol       Date:  2018-02-08       Impact factor: 1.909

9.  Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation.

Authors:  Paul Lohan; Nick Murphy; Oliver Treacy; Kevin Lynch; Maurice Morcos; Bingling Chen; Aideen E Ryan; Matthew D Griffin; Thomas Ritter
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

10.  The atypical chemokine receptor-2 does not alter corneal graft survival but regulates early stage of corneal graft-induced lymphangiogenesis.

Authors:  Tian Yu; J V Forrester; Gerard J Graham; Lucia Kuffova
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-27       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.